CareDx (CDNA) Jefferies Global Healthcare Conference 2026 summary

Business strategy and market focus

• Targeting leadership in precision medicine diagnostics, especially in high-cost, high-burden disease markets managed by subspecialty providers.

• Focused on transplantation, servicing over 200 U.S. solid organ transplant programs and performing over a million molecular tests.

• 70% of transplant centers use at least one digital solution; filled over 200,000 prescriptions for transplant patients last year.

• Growth strategy includes integrated testing, digital, and pharmacy solutions, leveraging a strong executive team and specialized workforce.

Financial performance and guidance

• Achieved 39% year-over-year revenue growth in Q1, with 17% growth in Testing Services volume.

• Adjusted EBITDA reached $18.9 million; ended the quarter with $189 million in cash and no debt.

• Updated 2024 guidance: $447M–$465M revenue, $43M–$57M adjusted EBITDA, 224,000–229,000 test volumes.

• Non-GAAP gross margin expected at 68%–71% per quarter; operating expenses at $68M–$70M per quarter.

Pipeline and innovation

• Key pipeline initiatives: AlloHeme for heme oncology, AlloSure Liver for solid organ transplant, HistoMap Kidney for kidney transplantation.

• AlloHeme targets AML and MDS relapse monitoring post-stem cell transplant, addressing an unmet need.

• Naveris acquisition adds a leading solid tumor MRD platform for viral-mediated cancers, expanding the portfolio.

• Naveris product has >95% PPV/NPV for HPV+ head and neck cancer, with a four-month lead time for recurrence detection.

• Pipeline expansion increases total addressable market (TAM) to $12.5 billion across multiple indications.